Vial Packaging Innovations from SGD Pharma at CPHI Frankfurt 2025

As part of its coverage of CPHI Frankfurt 2025, Pharmaceutical Technology® spoke with Najet Mebarki, director of Product Management & Innovation—Molded Glass at SGD Pharma.

Among the new innovations SGD Pharma is showing at the event is its flagship Sealian platform, an internal surface treatment for molded glass vials.

SGD Pharma will additionally roll out its recently launched Lab Services offering, designed to deliver analytical testing to players throughout the glass packaging space.

Mebarki says the innovations SGD Pharma will have on display at the event collectively reflect the company’s growing and ongoing commitment to sustainability and emission reduction goals.

Click here for all of our CPHI Frankfurt coverage. Click here to view the video version of this interview.

PharmTech: What are you displaying?

Mebarki (SGD Pharma): One of our very important innovations is Sealian, which is a unique internal treatment that confers additional functionality to the vial, and for which we have a strong competitive advantage thanks to this internal coating. It allows for a barrier effect and hydrophobic properties.

We will also showcase Idency, our latest premium molded vial that combines high mechanical strength and chemical durability. These are vials that combine the benefits of molded glass with the same outer diameter as [standard] tubular [glass]. We have developed a full range that will be available: 6 mL, 10 mL, and 20 mL. It's aimed at sensitive parenteral drugs [such as for] biotech, oncology, monoclonal antibodies, and the immunology and lyophilization markets.

[We will also display] Sterility, our ready-to-use offer that increases speed-to-market for customers.

For oral, we have Ensiemo, which is a full packaging solution for oral droppers, and now we also have a full packaging solution for syrup.

Proseal+ is an external treatment that is on the ceiling surface and guarantees an optimal ceiling, and it protects the drug from moisture or oxygen. As you may know, 50% of medicinal products degrade because of moisture.

Velocity, which is another treatment, is an external treatment that boosts production line efficiency and reduces particulate generation up to 96%.

Finally, we will launch a new service called the Lab Services, which is a comprehensive analytical portfolio. We are a glass expert with more than a century of know-how. And this analytical portfolio covers from pharmacopeia compliance studies to more advanced investigations and more specific customer needs, and it's suitable for both molded and tubular.

How will you be building on previous CPHI interactions?

We always have a great experience at CPHI, with our customers, our prospects, and our partners as well. It's a big moment of connection with these people, but also a big moment of networking.

Of course, a big moment for business, but not just business. It's also the moment where we follow trends, where we confirm trends, where we discuss these trends with our partners.

That's our biggest event of the year, actually, so the busiest one and the biggest, but each year it's always a success, and each year it's always different in a way. But yes—a moment to connect and to share.